Overview
Pyridoxamine-5-phosphate oxidase deficiency (also called PNPO deficiency or PMP oxidase deficiency) is a very rare inherited brain disorder that affects how the body processes vitamin B6. The body needs a specific form of vitamin B6 called pyridoxal-5-phosphate (PLP) to keep the brain working properly. In this condition, a faulty gene means the body cannot make enough PLP, which causes the brain to become starved of a critical chemical it needs to function. This leads to a type of severe brain disorder called a developmental and epileptic encephalopathy. The most striking feature of this disease is seizures that begin very early in life, often within hours or days of birth. These seizures are usually very hard to control with standard anti-seizure medicines. Babies may also show signs of brain distress before birth, such as abnormal movements in the womb. Without early treatment, the ongoing seizures cause serious damage to the developing brain, leading to intellectual disability and developmental delays. The good news is that this condition can be treated with vitamin B6 supplements, specifically pyridoxal-5-phosphate (PLP) or sometimes pyridoxine. Starting treatment as early as possible is critical to protecting the brain and improving outcomes. Children who are diagnosed and treated quickly have a better chance of reaching developmental milestones, though many still face ongoing challenges.
Also known as:
Key symptoms:
Seizures starting in the first days of life that are very hard to controlAbnormal brain electrical activity seen on EEGIntellectual disability or significant learning difficultiesDelayed development (sitting, walking, talking later than expected)Low muscle tone (floppy baby)Irritability and poor feeding in newbornsAbnormal eye movementsEpisodes of stopped breathing (apnea) in newbornsAbnormal movements or jerking before or after birthSmall head size (microcephaly) in some childrenBrain abnormalities visible on MRI scan
Clinical phenotype terms (29)— hover any for plain English
Autosomal recessive
Passed on when both parents carry the same gene change; often skips generations
Neonatal
Begins at or shortly after birth (first 4 weeks)
FDA & Trial Timeline
1 eventMedicure — PHASE3
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
No FDA-approved treatments are currently listed for Pyridoxamine-5-phosphate deficiency-developmental and epileptic encephalopathy.
1 clinical trialare actively recruiting — trials can provide access to cutting-edge therapies.
View clinical trials →Specialists
View all specialists →No specialists are currently listed for Pyridoxamine-5-phosphate deficiency-developmental and epileptic encephalopathy.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Pyridoxamine-5-phosphate deficiency-developmental and epileptic encephalopathy.
Community
No community posts yet. Be the first to share your experience with Pyridoxamine-5-phosphate deficiency-developmental and epileptic encephalopathy.
Start the conversation →Latest news about Pyridoxamine-5-phosphate deficiency-developmental and epileptic encephalopathy
Disease timeline:
New recruiting trial: Oral Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency
A new clinical trial is recruiting patients for Pyridoxamine-5-phosphate deficiency-developmental and epileptic encephalopathy
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.What is the best form and dose of vitamin B6 for my child, and how will we know if it is working?,How quickly should we expect seizures to improve after starting PLP treatment, and what should we do if they do not?,Should we do genetic testing on other family members, and what are the chances of this happening in a future pregnancy?,What therapies (physical, speech, occupational) should my child start, and how soon?,Are there any signs of vitamin B6 toxicity I should watch for at home?,Does my child need an emergency seizure rescue plan, and what medicines should we have at home?,Is there a newborn screening test available so future siblings could be diagnosed earlier?
Common questions about Pyridoxamine-5-phosphate deficiency-developmental and epileptic encephalopathy
What is Pyridoxamine-5-phosphate deficiency-developmental and epileptic encephalopathy?
Pyridoxamine-5-phosphate oxidase deficiency (also called PNPO deficiency or PMP oxidase deficiency) is a very rare inherited brain disorder that affects how the body processes vitamin B6. The body needs a specific form of vitamin B6 called pyridoxal-5-phosphate (PLP) to keep the brain working properly. In this condition, a faulty gene means the body cannot make enough PLP, which causes the brain to become starved of a critical chemical it needs to function. This leads to a type of severe brain disorder called a developmental and epileptic encephalopathy. The most striking feature of this dise
How is Pyridoxamine-5-phosphate deficiency-developmental and epileptic encephalopathy inherited?
Pyridoxamine-5-phosphate deficiency-developmental and epileptic encephalopathy follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Pyridoxamine-5-phosphate deficiency-developmental and epileptic encephalopathy typically begin?
Typical onset of Pyridoxamine-5-phosphate deficiency-developmental and epileptic encephalopathy is neonatal. Age of onset can vary across affected individuals.
Are there clinical trials for Pyridoxamine-5-phosphate deficiency-developmental and epileptic encephalopathy?
Yes — 1 recruiting clinical trial is currently listed for Pyridoxamine-5-phosphate deficiency-developmental and epileptic encephalopathy on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.